hotspot -WSS

hotspot

author：comprehensive 2025-09-30 15:16:04 - browse：65791

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Adults seen as increasingly susceptible to measles

focus

WSS

Physician groups backed by private equity giant lobby on mergers

The high personal cost of affirmative action for Black doctors

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Physicians and social media: If you see something, say something?

AstraZeneca to buy developer of next

Gene editing the human germline: What are the risks?

entertainment

hotspot

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Sage hopes for a blockbuster in antidepressant now before FDA

At least 13 dead in Texas as scorching temps continue

New safety details link Apellis eye drug to rare cases of blindness

Novavax promises a turnaround & Lilly roils the obesity market

Scientists inch closer to single

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Scientists inch closer to single

23andMe had bad news about my health. I wish a person had delivered it

What the US credit downgrade means for the economy, your finances

knowledge

The high personal cost of affirmative action for Black doctors

No plane should take off without an EpiPen onboard

Adults seen as increasingly susceptible to measles

Argenx readies a blockbuster opportunity with drug for autoimmune disease

What to expect as Trump is arraigned on his Jan 6. indictment

Virtual Event: March of the Biosimilars

focus

Wikipedia

hotspot

knowledge